Oseltamivir Treatment Guidelines for Influenza

Introduction to Oseltamivir Treatment

The Centers for Disease Control and Prevention recommends that oseltamivir should be given to high-risk patients, severely ill patients, and hospitalized patients even beyond 48 hours of symptom onset 1, 2, 3

The American Academy of Pediatrics and the Centers for Disease Control and Prevention suggest that oseltamivir treatment should not be withheld from hospitalized patients, high-risk patients, or those with severe, complicated, or progressive illness, regardless of the time since symptom onset 1, 2, 3
High-risk populations requiring treatment beyond 48 hours include immunocompromised patients, pregnant and postpartum women, children under 2 years of age, adults 65 years and older, and patients with chronic medical conditions 1, 3

The World Health Organization and the Centers for Disease Control and Prevention recommend starting oseltamivir immediately in high-risk patients, hospitalized patients, and severely ill patients, without waiting for laboratory confirmation 1, 3
Treatment initiated within 48 hours of symptom onset reduces illness duration by approximately 1-1.5 days, but oseltamivir remains effective even when started later in high-risk and hospitalized patients 3, 4

Oseltamivir reduces the risk of pneumonia by 50% and decreases mortality in hospitalized patients (OR = 0.21) 3
The treatment also decreases antibiotic use and hospitalization rates, and reduces the risk of otitis media in children by 34% 3, 4

Common adverse effects of oseltamivir include nausea (3.66% increased risk) and vomiting (4.56% increased risk in adults, 5.34% in children), which are usually transient and mild 3